KBC Group NV Acquires Shares of 36,932 Castle Biosciences, Inc. $CSTL

KBC Group NV bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 36,932 shares of the company’s stock, valued at approximately $907,000. KBC Group NV owned 0.12% of Castle Biosciences as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of CSTL. Amundi boosted its holdings in Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Castle Biosciences by 548.9% during the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock valued at $2,743,000 after acquiring an additional 115,907 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after acquiring an additional 655 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Castle Biosciences by 34.7% in the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after acquiring an additional 8,992 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity

In related news, COO Kristen M. Oelschlager sold 8,587 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $20.71, for a total value of $177,836.77. Following the transaction, the chief operating officer directly owned 30,460 shares in the company, valued at approximately $630,826.60. This represents a 21.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 6,214 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $22.15, for a total value of $137,640.10. Following the completion of the transaction, the insider owned 21,479 shares of the company’s stock, valued at $475,759.85. The trade was a 22.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 45,189 shares of company stock worth $1,014,561 over the last quarter. 6.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on the company. KeyCorp set a $35.00 price target on Castle Biosciences in a research report on Friday, May 29th. Roth Capital assumed coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 target price on the stock. Weiss Ratings lowered shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Finally, Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.43.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $24.68 on Friday. The stock’s fifty day moving average is $22.20 and its two-hundred day moving average is $27.02. The firm has a market capitalization of $748.54 million, a P/E ratio of -56.09 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). The business had revenue of $84.23 million during the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. On average, research analysts anticipate that Castle Biosciences, Inc. will post -1.56 earnings per share for the current year.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.